On Tuesday, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) opened higher 14.08% from the last session, before settling in for the closing price of $4.90. Price fluctuations for ENTA have ranged from $4.71 to $17.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -19.00%. Company’s average yearly earnings per share was noted 23.67% at the time writing. With a float of $19.86 million, this company’s outstanding shares have now reached $21.33 million.
The extent of productivity of a business whose workforce counts for 131 workers is very important to gauge. In terms of profitability, gross margin is 98.13%, operating margin of -179.92%, and the pretax margin is -174.15%.
Enanta Pharmaceuticals Inc (ENTA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Enanta Pharmaceuticals Inc is 6.90%, while institutional ownership is 103.57%. The most recent insider transaction that took place on Dec 06 ’24, was worth 18,401. In this transaction Chief Product Strategy Officer of this company sold 2,283 shares at a rate of $8.06, taking the stock ownership to the 29,305 shares. Before that another transaction happened on Dec 06 ’24, when Company’s Chief Business Officer sold 2,283 for $8.06, making the entire transaction worth $18,401. This insider now owns 36,047 shares in total.
Enanta Pharmaceuticals Inc (ENTA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 23.67% per share during the next fiscal year.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Trading Performance Indicators
Check out the current performance indicators for Enanta Pharmaceuticals Inc (ENTA). In the past quarter, the stock posted a quick ratio of 5.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.95, a number that is poised to hit -1.15 in the next quarter and is forecasted to reach -4.11 in one year’s time.
Technical Analysis of Enanta Pharmaceuticals Inc (ENTA)
The latest stats from [Enanta Pharmaceuticals Inc, ENTA] show that its last 5-days average volume of 0.52 million was inferior to 0.52 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 38.17%. Additionally, its Average True Range was 0.38.
During the past 100 days, Enanta Pharmaceuticals Inc’s (ENTA) raw stochastic average was set at 10.16%, which indicates a significant decrease from 68.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.91% in the past 14 days, which was higher than the 64.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.05, while its 200-day Moving Average is $10.82. Now, the first resistance to watch is $5.97. This is followed by the second major resistance level at $6.36. The third major resistance level sits at $6.73. If the price goes on to break the first support level at $5.22, it is likely to go to the next support level at $4.85. The third support level lies at $4.46 if the price breaches the second support level.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Key Stats
There are currently 21,333K shares outstanding in the company with a market cap of 119.25 million. Presently, the company’s annual sales total 67,640 K according to its annual income of -116,050 K. Last quarter, the company’s sales amounted to 14,610 K and its income totaled -28,820 K.
